Sheets Kerry M, Davey Cynthia S, St Peter Wendy L, Reule Scott A, Murray Anne M
Department of Medicine, Division of Geriatrics and Palliative Care Hennepin Healthcare Minneapolis Minnesota USA.
Biostatistical Design and Analysis Center University of Minnesota Clinical and Translational Science Institute Minneapolis Minnesota USA.
Health Sci Rep. 2022 Jun 29;5(4):e697. doi: 10.1002/hsr2.697. eCollection 2022 Jul.
Reduced estimated glomerular filtration rate (eGFR < 60 ml/min/1.73 m) is a risk factor for cognitive impairment (CI) and medication nonadherence. However, the association between CI and medication adherence in adults with reduced eGFR has not been adequately examined. Our pragmatic objectives were to assess the cross-sectional relationship between CI and self-reported medication adherence, medication number, and use of potentially high-risk medications among adults with reduced eGFR.
An observational cohort study of the epidemiology of CI in community-dwelling adults aged 45 years or older with reduced eGFR.
Our analytic cohort consisted of 420 participants (202 with CI; mean age: 69.7 years) with reduced eGFR, at least one prescription medication, and nonmissing medication adherence data. Participants with CI had four times greater unadjusted odds of reporting good medication adherence than participants without CI (self-report of missing medications <4 days/month; odds ratio [OR]: 4.04, 95% confidence interval [CI]: 1.62-10.10). This difference persisted following adjustment for demographic factors and comorbidities (OR: 5.50, 95% CI: 1.86-16.28). Participants with CI were no more likely than participants without CI to report forgetfulness as a reason for missing medication doses. Participants with CI were, on average, taking more total (mean: 13.3 vs. 11.5, median: 12 vs. 11) and more high-risk (mean: 5.0 vs. 4.2, median: 5 vs. 4) medications than those without CI; these differences were attenuated and no longer significant following adjustment for demographics and comorbidities.
Given the well-documented association between CI and medication nonadherence, better self-reported medication adherence among those with CI may represent perceptions of adherence rather than actual adherence. Participants with CI were, on average, taking more total and more high-risk medications than those without CI, suggesting a possible increased risk for adverse drug events. Our results highlight the potential risks of relying on self-reported medication adherence in reduced eGFR patients with CI.
估算肾小球滤过率降低(eGFR<60ml/min/1.73m²)是认知障碍(CI)和药物治疗依从性差的危险因素。然而,eGFR降低的成年人中CI与药物治疗依从性之间的关联尚未得到充分研究。我们的实际目标是评估eGFR降低的成年人中CI与自我报告的药物治疗依从性、用药数量以及使用潜在高风险药物之间的横断面关系。
对45岁及以上社区居住且eGFR降低的成年人中CI的流行病学进行观察性队列研究。
我们的分析队列由420名参与者组成(202名患有CI;平均年龄:69.7岁),他们eGFR降低,至少有一种处方药,且有完整的药物治疗依从性数据。与无CI的参与者相比,患有CI的参与者报告良好药物治疗依从性的未调整比值比高出四倍(自我报告漏服药物<4天/月;比值比[OR]:4.04,95%置信区间[CI]:1.62 - 10.10)。在对人口统计学因素和合并症进行调整后,这种差异仍然存在(OR:5.50,95%CI:1.86 - 16.28)。与无CI的参与者相比,患有CI的参与者将忘记服药作为漏服药物剂量原因的可能性并无增加。患有CI的参与者平均服用的药物总数(平均值:13.3对11.5,中位数:12对11)和高风险药物更多(平均值:5.0对4.2,中位数:5对4);在对人口统计学和合并症进行调整后这些差异减弱且不再显著。
鉴于CI与药物治疗不依从之间有充分记录的关联,CI患者中更好地自我报告药物治疗依从性可能代表对依从性的认知而非实际依从性。患有CI的参与者平均服用的药物总数和高风险药物比无CI的参与者更多,这表明药物不良事件的风险可能增加。我们的结果强调了在eGFR降低且患有CI的患者中依赖自我报告的药物治疗依从性的潜在风险。